For an adult population of 10 million an overall decrease in number of AIDS deaths of about 4540 per year (−13 000 to −300) across 50 years is predicted, with little discernible benefit with NAT when compared with standard antibody-based rapid testing. The gene discussed is BRD2; the disease is AIDS.